Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Local Cytoreductive Treatments for Men With Newly Diagnosed Metastatic Prostate Cancer in Addition to Standard of Care Treatment

NCT03763253 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT03763253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03763253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Local Cytoreductive Treatments for Men With Newly Diagnosed Metastatic Prostate Cancer in Addition to Standard of Care Treatment
Lead sponsor
Imperial College London
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 10, 2019
Completion date
January 31, 2027
Enrollment
433 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer, prostate cancer